Search results
'Yes, we did' fund Wuhan gain-of-function research, 'virtually every lab' does it: NIH official
Just the News· 16 hours agoPresident Clinton's infamous parsing of the word "is" remains apt 26 years after his deposition in...
Long Dismissed, Chronic Lyme Is Finally in the Spotlight
Time via AOL· 20 hours agoNational Institute of Allergy and Infectious Diseases (NIAID) last year awarded $3 million in...
Biden Administration Strips Federal Funding From Nonprofit at Center of COVID Lab Leak Controversy
Reason.com via Yahoo News· 2 days agoFederal officials say EcoHealth Alliance failed to properly report on its gain-of-function research...
Column: Democrats show that they're no better than Trump in allowing politics to interfere with...
LA Times via Yahoo News· 5 hours agoEcoHealth Alliance, which developed research allowing humankind to defeat the next viral pandemic,...
Stop Spending Tax Dollars on NIH's Cruel Animal Experiments
Newsweek· 3 days agoProject's (WCW) viral #BeagleGate campaign uncovered that Dr. Fauci's division of the NIH—the...
NIH quietly altered definition for gain-of-function research on its website, former Fauci aide...
BizPac Review· 22 hours agoNational Institutes of Health (NIH) Principal Deputy Director Lawrence Tabak confirmed on Thursday that his agency’s communications department altered NIH’s definition of gain-of-function research ...
Chronic Lyme Disease: Why COVID May Spark Better Tests and Treatment
Well and Good· 2 days agoPeople with chronic Lyme disease (or PTLDS) are understudied and have limited treatment options, but...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 3 days agoOcugen, Inc. (NASDAQ: NASDAQ:OCGN) discussed significant advancements in its gene therapy programs...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 days agoFortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoAll three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets